Advance in MicroRNAs and EGFR-TKIs Secondary Resistance Research in Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2014.12.07
- VernacularTitle:非小细胞肺癌中microRNAs与EGFR-TKIs继发性耐药机制的研究进展
- Author:
DUAN XIAOYANG
1
;
SHI JIAN
Author Information
1. 河北医科大学
- Keywords:
Lung neoplasms;
MicroRNAs;
EGFR-TKIs;
Secondary resistance
- From:
Chinese Journal of Lung Cancer
2014;(12):860-864
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only inlfuence the drug sensitivity, appear even disease progression, become the main bottleneck of its curative effect. MicroRNAs (miRNAs) is a non coding RNA and protein involved in regulating gene expression in the transcription level. Recent studies found that miRNAs involved in EGFR-TKIs resistance, which affect the sensitivity of tumor cells to treatment. In this paper, we reviewed brielfy advance in miRNAs and EGFR-TKIs secondary resis-tance research in NSCLC.
